Beam Therapeutics BEAM reported a loss of $1.09 per share for the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had recorded earnings ...
Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Beam Therapeutics in a report issued on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback